

## Alectinib

### for adjuvant treatment of resectable, ALK mutation-positive non-small-cell lung cancer

Technology Guidance from the MOH Drug Advisory Committee

#### Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has not recommended alectinib for inclusion on the MOH List of Subsidised Drugs for adjuvant treatment of resectable, anaplastic lymphoma kinase mutation-positive non-small-cell lung cancer. The decision was due to the unacceptable pricing and price-volume agreement proposed by the company.

***Clinical indication, subsidy class and MediShield Life claims eligibility for alectinib are provided in the Annex.***

## ANNEX

### Recommendations by the MOH Drug Advisory Committee

Drug preparation	Approved clinical indication	Subsidy class	Eligible for MediShield Life claims (implementation date)
Alectinib 150 mg capsule	Adjuvant treatment as monotherapy after tumour resection in patients with stage II to IIIA or stage IIIB (T3N2), ALK mutation-positive NSCLC, according to the 8th edition of the AJCC/UICC cancer staging system. Treatment should be continued until disease recurrence, unacceptable toxicity, or for a maximum of 2 years.	Not recommended for subsidy	Yes <sup>1</sup> (1 Nov 2025)

Abbreviations: ALK, anaplastic lymphoma kinase; AJCC/UICC: American Joint Committee on Cancer/International Union Against Cancer; NSCLC, non-small-cell lung cancer

<sup>1</sup> Please refer to [MOH's website](#) for the MediShield Life claim limit starting from the implementation date.

## VERSION HISTORY

### Guidance on alectinib for adjuvant treatment of resectable, ALK mutation-positive non-small-cell lung cancer

This Version History is provided to track any updates or changes to the guidance following the first publication date. It is not part of the guidance.

- |    |   |             |
|----|---|-------------|
| 1. | <b>Publication of guidance</b>  |             |
|    | Date of Publication   | 2 Jun 2025  |
| 2. | <b>Guidance updated to include alectinib on the Cancer Drug List</b>  |             |
|    | Date of Publication   | 16 Sep 2025 |
| 3. | <b>Guidance updated to reflect MediShield Life claims eligibility</b> |             |
|    | Date of Publication   | 1 Jun 2026  |

 Agency for Care Effectiveness - ACE  Agency for Care Effectiveness (ACE)

#### About the Agency

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidance, and education.

As the national HTA agency, ACE conducts evaluations to inform government funding decisions for treatments, diagnostic tests and vaccines, and produces guidance for public hospitals and institutions in Singapore.

The guidance is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition. The responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

Find out more about ACE at <https://www.ace-hta.gov.sg/about-us/>

#### © Agency for Care Effectiveness, Ministry of Health, Republic of Singapore

All rights reserved. Reproduction of this publication in whole or in part in any material form is prohibited without the prior written permission of the copyright holder. Requests to reproduce any part of this publication should be addressed to:

Agency for Care Effectiveness, Ministry of Health, Singapore  
Email: [ACE@moh.gov.sg](mailto:ACE@moh.gov.sg)

In citation, please credit "Agency for Care Effectiveness, Ministry of Health, Singapore" when you extract and use the information or data from the publication.